-
Promising advances are being made on the microbicide front: U.S. funding appears imminent for microbicide research and development, a new corporate partnership has been struck with an international research group to step up testing of antiviral AIDS gels, and a number of potential candidates are moving through the research pipeline.
-
Did the office telephone lines start buzzing when the media broadcasted reports of adverse events linked to use of the transdermal contraceptive Ortho Evra? Theres no doubt that clinicians have, since those reports, fielded many questions about the safety of the patch, which has been used by about 4 million women since its November 2001 approval by the Food and Drug Administration (FDA).
-
Tissue Doppler echocardiography can distinguish between constrictive pericarditis and restrictive cardiomyopathy.
-
Doppler echocardiography can estimate SVR, and is particularly accurate at identifying a low SVR.
-
Focal left atrial tachycardias are an important complication after pulmonary vein isolation.
-
During the last few years, chronic kidney disease has been increasingly recognized as a significant risk factor for the development of cardiovascular disease. An American Heart Association Scientific Statement reviewing this subject was published last fall.
-
-
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
-
-
Good news for family planning providers: Salary levels are reflecting a modest increase in 2004, according to the results of the annual Contraceptive Technology Update salary survey. The survey was mailed in July 2004 to 1,247 subscribers and had a response of 229, for a response rate of 18.36%.
